Steven Cohen’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-573,700
| Closed | -$23.6M | – | 4492 |
|
|
2025
Q4 | $23.2M | Buy |
+573,700
| New | +$13.3M | 0.03% | 789 |
|
|
2025
Q2 | – | Sell |
-160,725
| Closed | -$444K | – | 2608 |
|
|
2025
Q1 | $444K | Sell |
160,725
-1,091,116
| -87% | -$4.46M | ﹤0.01% | 1657 |
|
|
2024
Q4 | $6.94M | Sell |
1,251,841
-1,455,674
| -54% | -$9.86M | 0.02% | 840 |
|
|
2024
Q3 | $22.6M | Buy |
2,707,515
+17,139
| +0.6% | +$141K | 0.06% | 383 |
|
|
2024
Q2 | $18.3M | Buy |
2,690,376
+469,176
| +21% | +$2.84M | 0.05% | 421 |
|
|
2024
Q1 | $14.6M | Buy |
+2,221,200
| New | +$14.5M | 0.04% | 568 |
|
|
2023
Q4 | – | Sell |
-571,265
| Closed | -$2.87M | – | 2809 |
|
|
2023
Q3 | $2.87M | Buy |
+571,265
| New | +$3.63M | 0.01% | 1043 |
|
|
2023
Q2 | – | Sell |
-629,098
| Closed | -$7.45M | – | 2777 |
|
|
2023
Q1 | $7.45M | Buy |
629,098
+395,598
| +169% | +$3.78M | 0.02% | 639 |
|
|
2022
Q4 | $2.38M | Buy |
+233,500
| New | +$1.55M | 0.01% | 909 |
|
|
2022
Q3 | – | Sell |
-500,000
| Closed | -$1.24M | – | 1727 |
|
|
2022
Q2 | $1.24M | Buy |
500,000
+377,427
| +308% | +$754K | 0.01% | 1029 |
|
|
2022
Q1 | $364K | Buy |
+122,573
| New | +$523K | ﹤0.01% | 1037 |
|
Other funds holding TERN
Steven Cohen's TERN Position: Q1 2026 in Review
Steven Cohen sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 573,700 shares — an estimated $23.6M sold.
Steven Cohen first reported a position in TERN in Q1 2022 and held it in 11 quarters. The position peaked at $23.2M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.
- Steven Cohen reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Steven Cohen sold 573,700 Terns Pharmaceuticals shares in Q1 2026, an estimated $23.6M.
- Steven Cohen first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 11 quarters.
- Steven Cohen's Terns Pharmaceuticals position peaked at $23.2M in Q4 2025.
- 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.